Rino Rappuoli
Rino Rappuoli ForMemRS (born 4 August 1952) is an
Italian immunologist. He is the head of vaccine Rino Rappuoli
ForMemRS
research and development (R&D) at GlaxoSmithKline
(GSK) Vaccines.[1] Previously, he has served as
visiting scientist at Rockefeller University and Harvard
Medical School and held roles at Sclavo, Vaccine
Research and CSO, Chiron Corporation, and Novartis
Vaccines.[3][4][5]
Education
Rappuoli earned his doctoral and bachelor's degrees in
biological sciences at the University of Siena.[6]
Career and research Rappuoli in 2016
He is known globally for his work in vaccines and Born 4 August 1952[2]
immunology. He co-founded the field of cellular Radicofani, Italy
microbiology, a discipline combining cell biology and Scientific career
microbiology, and pioneered the genomic approach to Fields Vaccines
vaccine development known as reverse vaccinology, a
Infectious diseases
subsection of reverse pharmacology.[6]
Global health[1]
Rappuoli led Chiron Corporation's development of Website [Link]/about-aditec
adjuvanted influenza vaccines, MENJUGATE(R) /project-management/dr-rino-rappuoli
conjugate vaccine against meningococcal-C disease .html ([Link]
and the first recombinant bacterial vaccine against ut-aditec/project-management/dr-rino
pertussis. Currently, Rappuoli is actively involved in -[Link])
the research and development of further vaccines
against meningococcal disease and avian and pandemic influenza.
Rappuoli joined Chiron as head of European vaccines research in 1992 with the acquisition of Italian
vaccines company Sclavo SpA, where he served as head of research and development. Rappuoli, was
previously the global head of vaccines research for Novartis Vaccines & Diagnostics (Siena, Italy)[6]
Since 2015, Dr. Rappuoli serves as the chief scientist and head of external R&D at the vaccines division
of GlaxoSmithKline and is based in Siena, Italy.[7]
Major achievements include development of CRM197[8] used in Haemophilus influenzae, Neisseria
meningitidis,[9] and pneumococcus vaccines; an acellular pertussis vaccine containing a genetically
detoxified pertussis toxin; the first conjugate vaccines against meningococcus; MF59 adjuvant for
influenza;[10][11] the meningococcus B genome-derived vaccine.[3][12]
During his career, he has introduced several novel scientific concepts: genetic detoxification in 1987;[13]
cellular microbiology in 1996;[14] reverse vaccinology in 2000;[15] pan-genome in 2005.[3][16]
Honors and awards
Rappuoli is the recipient of several prestigious awards, including the Paul Ehrlich and Ludwig
Darmstaedter Prize in 1991. He is a member of numerous international associations, including the
European Molecular Biology Organization and the American Society for Microbiology. He also serves as
a member of the research directors group of the European Commission and was elected to National
Academy of Sciences of the United States. He was also awarded the Italian President Gold Medal in 2005
and the Albert Sabin Gold Medal in 2009.[3] In 2013 he was nominated third most influential person
worldwide in the field of vaccines by Terrapin. In 2015 he was awarded Fellowship of Imperial College
London Faculty of Medicine and the Maurice Hilleman Award.[3]
In 2016 he was elected a Foreign Member of the Royal Society.[3]
In 2017 he received the European Inventor Award 2017 in the category of "Lifetime achievement" by the
European Patent Office.[17] In 2019 he was awarded the Robert Koch Prize.[18]
References
1. Rino Rappuoli ([Link] publications
indexed by Google Scholar
2. "Curriculum vitae Rino Rappuoli" ([Link]
[Link]/images/trasparente/CV_R.[Link]) (PDF).
[Link]. 2014-06-01. Archived from the original ([Link]
[Link]/images/trasparente/CV_R.[Link]) (PDF) on 2018-04-11.
3. Anon (2016). "Dr Rino Rappuoli ForMemRS" ([Link]
3/[Link] London: Royal Society. Archived from
the original ([Link] on 2016-04-29. One or
more of the preceding sentences incorporates text from the [Link] website where:
All text published under the heading 'Biography' on Fellow profile pages is
available under Creative Commons Attribution 4.0 International License." --"Royal
Society Terms, conditions and policies" ([Link]
834/[Link] Archived from the
original on September 25, 2015. Retrieved 2016-03-09.
4. Covacci, A. (1999). "Helicobacter pylori Virulence and Genetic Geography". Science. 284
(5418): 1328–1333. Bibcode:1999Sci...284.1328C ([Link]
ci...284.1328C). doi:10.1126/science.284.5418.1328 ([Link]
4.5418.1328). PMID 10334982 ([Link]
5. Anon (2007). "Rino Rappuoli" ([Link] Nature Reviews Drug
Discovery. 6 (9): 694. doi:10.1038/nrd2419 ([Link]
PMID 17907342 ([Link] S2CID 40012743 ([Link]
[Link]/CorpusID:40012743).
6. Trivedi, B. (2006). "Profile of Rino Rappuoli" ([Link]
1544134). Proceedings of the National Academy of Sciences. 103 (29): 10831–10833.
Bibcode:2006PNAS..10310831T ([Link]
T). doi:10.1073/pnas.0604892103 ([Link]
PMC 1544134 ([Link] PMID 16832044
([Link]
7. "Dr Rino Rappuoli" ([Link]
eu/about-aditec/project-management/[Link]). Archived from the original (htt
p://[Link]/about-aditec/project-management/[Link]) on 2017-
03-05. Retrieved 2016-01-28.
8. Bröker, Michael; Costantino, Paolo; DeTora, Lisa; McIntosh, E. David; Rappuoli, Rino
(2011). "Biochemical and biological characteristics of cross-reacting material 197
(CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines
and other potential clinical applications". Biologicals. 39 (4): 195–204.
doi:10.1016/[Link].2011.05.004 ([Link]
PMID 21715186 ([Link]
9. Tettelin, H. (2000). "Complete Genome Sequence of Neisseria meningitidis Serogroup B
Strain MC58". Science. 287 (5459): 1809–1815. Bibcode:2000Sci...287.1809. ([Link]
[Link]/abs/2000Sci...287.1809.). doi:10.1126/science.287.5459.1809 ([Link]
rg/10.1126%2Fscience.287.5459.1809). PMID 10710307 ([Link]
10710307).
10. O'Hagan, Derek T; Ott, Gary S; Nest, Gary Van; Rappuoli, Rino; Giudice, Giuseppe Del
(2014). "The history of MF59® adjuvant: a phoenix that arose from the ashes". Expert
Review of Vaccines. 12 (1): 13–30. doi:10.1586/erv.12.140 ([Link]
2.140). PMID 23256736 ([Link] S2CID 7842318 (http
s://[Link]/CorpusID:7842318).
11. O'Hagan, Derek T; Rappuoli, Rino; De Gregorio, Ennio; Tsai, Theodore; Del Giudice,
Giuseppe (2014). "MF59 adjuvant: the best insurance against influenza strain diversity".
Expert Review of Vaccines. 10 (4): 447–462. doi:10.1586/erv.11.23 ([Link]
6%2Ferv.11.23). PMID 21506643 ([Link]
S2CID 20377287 ([Link]
12. Pizza, M. (2000). "Identification of Vaccine Candidates Against Serogroup B Meningococcus
by Whole-Genome Sequencing". Science. 287 (5459): 1816–1820.
Bibcode:2000Sci...287.1816. ([Link]
doi:10.1126/science.287.5459.1816 ([Link]
PMID 10710308 ([Link] S2CID 43349049 ([Link]
[Link]/CorpusID:43349049).
13. Pizza, Mariagrazia; Fontana, Maria Rita; Scarlato, Vincenzo; Rappuoli, Rino (1996).
"Genetic Detoxification of Bacterial Toxins". Vaccine Protocols. 4: 91–110. doi:10.1385/0-
89603-334-1:91 ([Link] ISBN 0-89603-334-1.
PMID 21359697 ([Link]
14. Cossart, P.; Boquet, P.; Normark, S.; Rappuoli, R. (1996). "Cellular Microbiology Emerging".
Science. 271 (5247): 315–316. Bibcode:1996Sci...271..315C ([Link]
abs/1996Sci...271..315C). doi:10.1126/science.271.5247.315 ([Link]
ience.271.5247.315). PMID 8553065 ([Link]
S2CID 32437757 ([Link]
15. Rappuoli, Rino (2001). "Reverse vaccinology, a genome-based approach to vaccine
development". Vaccine. 19 (17–19): 2688–2691. doi:10.1016/S0264-410X(00)00554-5 (http
s://[Link]/10.1016%2FS0264-410X%2800%2900554-5). PMID 11257410 ([Link]
[Link]/11257410).
16. Medini, Duccio; Donati, Claudio; Tettelin, Hervé; Masignani, Vega; Rappuoli, Rino (2005).
"The microbial pan-genome". Current Opinion in Genetics & Development. 15 (6): 589–594.
doi:10.1016/[Link].2005.09.006 ([Link]
PMID 16185861 ([Link]
17. "European Patent Office. European Inventor Award 2017, Venice, june 15 2017" ([Link]
[Link]/web/20180402103401/[Link]
html). Archived from the original ([Link]
l) on 2018-04-02. Retrieved 2017-06-20.
18. Robert Koch Prize 2019 ([Link]
0)
Retrieved from "[Link]
